Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

As an orthopedic and sports medicine surgeon and chairman at Inova Sports Medicine, Dr. Robin West is no stranger to sports-related injuries. She understands that developing an effective game plan to ...

By consistently counteracting the excessive activation of neurons, AP-325 has the potential to revolutionize neuropathic pain management. “These results mark a significant step towards our ...

While New Orleans prepares for the excitement of the big game, it’s important to remember that sports injuries aren’t limited to the professionals. High school athletes, weekend warriors, and generall ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

While cannabinoids offer a potential alternative for refractory chronic pain, optimal use requires personalized dosing and ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be ...